Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 13/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 13/20 | 0.53 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | CLK2 | P49760 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL18038208 | 0.94 | ROCK1 (0.51) | ROCK1ROCK2DYRK3CLK1CLK2 | |
| SCHEMBL18056242 | 0.85 | ROCK1 (0.57) | ROCK1ROCK2 | |
| SCHEMBL18038323 | 0.85 | ROCK1 (0.73) | ROCK1ROCK2DYRK3CLK1CLK2 | |
| SCHEMBL18056356 | 0.82 | ROCK1 (0.65) | ROCK1ROCK2 | |
| Trifluoroacetic Acid SCHEMBL18038117 | 0.81 | ROCK2 (0.52) | ROCK1ROCK2DYRK3CLK1CLK2 | |
| Trifluoroacetic Acid SCHEMBL18038244 | 0.81 | ROCK1 (0.53) | ROCK1ROCK2DYRK3CLK1CLK2 | |
| SCHEMBL18056232 | 0.79 | ROCK2 (0.69) | ROCK1ROCK2 | |
| SCHEMBL18056328 | 0.79 | ROCK1 (0.57) | ROCK1ROCK2 | |
| SCHEMBL18038334 | 0.77 | ROCK2 (0.66) | ROCK1ROCK2 | |
| SCHEMBL21348811 | 0.76 | ROCK2 (0.60) | ROCK1ROCK2DYRK3CLK1CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180093978-A1 | INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-04-05 | — | — | US | disclosed |
| WO-2016138335-A1 | INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | LYCERA CORPORATION (US) | 2016-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093978-A1 | INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | ROCK1, ROCK2, CIT | ROCK1 1/4885ROCK2 2/4885DYRK3 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.